Tufts University

UC Davis Brain-Computer Interface Achieves 97% Accuracy in Speech Translation, Wins Top Clinical Research Award

3 months ago

• UC Davis researchers, led by Dr. David Brandman, developed a groundbreaking brain-computer interface that translates brain signals to speech with unprecedented 97% accuracy, earning a 2025 Top Ten Clinical Research Achievement Award. • The revolutionary technology successfully restored communication for a patient with ALS, enabling speech translation within minutes of system activation through implanted brain sensors. • The BrainGate2 clinical trial breakthrough, published in the New England Journal of Medicine, offers new hope for patients with paralysis and neurological conditions who have lost their ability to speak.

Enlivex Therapeutics Initiates Phase I Trial of Allocetra™ for Psoriatic Arthritis

6 months ago

• Enlivex Therapeutics has dosed the first patient in a Phase I clinical trial evaluating Allocetra™ for psoriatic arthritis, with no initial safety concerns. • The trial aims to enroll six patients unresponsive to conventional treatments, assessing safety and changes in pain and disease activity over 12 months. • Allocetra™, an off-the-shelf cell therapy, seeks to reprogram macrophages to their homeostatic state, potentially offering a novel approach for inflammatory conditions. • The psoriatic arthritis treatment market is projected to reach $20.5 billion by 2032, highlighting the need for more effective and safer therapies.

AVMA Veterinary Clinical Trials Registry Highlights New Studies in Canine and Feline Oncology and Neurological Disorders

8 months ago

• The AVMA Veterinary Clinical Trials Registry lists studies for animal health, connecting researchers with veterinarians and owners. • North Carolina State University is exploring a novel treatment approach for oral cancer in cats. • Several studies are investigating canine cancers, including hemangiosarcoma, osteosarcoma, and mast cell tumors, with innovative therapies. • Research is underway to assess treatments for canine cognitive dysfunction and degenerative myelopathy, mirroring human neurological conditions.